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Vascular surgery has matured to the point that there exists robust bodies of literature exploring many of our therapies.
However, this evidence is but one of the factors that dictate medical practice. Others include local patient demographics,
the practical implications of healthcare delivery, and an individual surgeon’s interpretation of this evidence, which can be
somewhat subjective. As a result, there are numerous examples of vascular specialists’ practice patterns differing
depending on their geographic location. Recognizing this, the Editors of the Journal of Vascular Surgery and the
European Journal of Vascular and Endovascular Surgery have developed a series of Trans-Atlantic Debates to explore
these instances. The inaugural debate explores the controversial question of how best to manage asymptomatic carotid
artery stenoses. Our debators, Peter Schneider and Ross Naylor, offer reasoned and passionate arguments to defend their
differing approaches. We trust that this addition to our journals will prove enlightening and, perhaps, entertaining.
(J Vasc Surg 2010;52:499-507.)PART I: CAROTID ENDARTERECTOMY OR
STENTING IN ADDITION TO MEDICAL
THERAPY IS STILL THE BEST WAY TO TREAT
MOST ASYMPTOMATIC PATIENTS WITH 60%
TO 99% CAROTID STENOSIS.
—Dr Peter A. Schneider
Repair of carotid stenosis, in addition to best medical
therapy (BMT), is currently the best way to treat most
asymptomatic patients with 60% to 99% carotid stenosis.
Carotid stenosis causes preventable strokes. The unfortu-
nates who present with stroke due to carotid stenosis (and
their even more unfortunate counterparts who experienced
a fatal stroke as the first sign of trouble) all harbored an
asymptomatic lesion before their respective events. Carotid
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doi:10.1016/j.jvs.2010.05.063repair used judiciously in concert with BMT and performed
well can have life-long protective effects against stroke-
related death and disability for patients with asymptomatic
carotid stenosis.1-3
There is a difference between critical analysis and being
unreasonably critical. Reckless claims have been made
about the superiority of BMT alone for 60% to 99% carotid
stenosis.4-7 Small patient cohorts that have included minor
lesions with limited follow-up have done “well” with BMT
alone and that has been used to advocate the cessation of
carotid repair.8-13 Practitioners have been accused of self-
enrichment as the motivation for carotid repair.14 We are
proudly informed that in the United Kingdom, only 20% of
patients undergoing CEA are being treated for asymptom-
atic carotid stenosis, while many times that number who
could benefit from repair will go on to have preventable
stroke.14,15
This leads to the following points:
1. Each time repair plus BMT has been compared with
BMT alone, repair has had significant and lasting bene-
fits.1-3 There are numerous current organizational
guidelines recommending repair and detailing the ben-
efits (Table I).16-19
2. Anyone who believes that they are performing carotid
repair for their own benefit and not for the benefit of the
patient should stop doing it immediately.14
3. BMT has produced stroke reduction in a variety of popu-
lations but has not been well tested among good-risk
patients with significant asymptomatic carotid stenosis
who would otherwise be candidates for repair.5,8,9,20-24
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management and has been performed with lower risk
than before (Table II).1,2,25-28 Antiplatelet agents and
statins have made repair as much as 50% safer.26,29-32
The small long-term annual risk of ipsilateral stroke of
about 0.5% in repair patients may be even smaller when
BMT is optimized.
5. Current research will help guide therapy by identifying
those most likely to benefit from repair in addition to
BMT and those who are at high risk for repair and
therefore, less likely to benefit.7,10,11,13,26,33,34
6. Consideration should be given to a randomized trial of
BMT alone vs BMT plus repair, but this will likely take
a decade to plan and conduct.
WHAT IS THE EVIDENCE FOR REPAIR (IN
ADDITION TO MEDICAL MANAGEMENT)?
After a significant carotid stenosis has developed, that
lesion remains a threat to the patient until it is removed. In
the Asymptomatic Carotid Surgery Trial (ACST), for ex-
ample, the annual risk of stroke after repair (0.55%) was
much less than the annual risk with BMT alone (1.9%).1
The Asymptomatic Carotid Atherosclerosis Study (ACAS)
and ACST studies both compared carotid endarterectomy
(CEA) plus BMT vs BMT alone, and both studies demon-
strated a decreased risk of stroke by approximately 50% at 5
years, even though both studies were biased against re-
pair.1,2
The risk of repair is front-loaded and the downside is
evident 30 days. BMT is “pay-as-you-go,” and the risks
only become evident over time. The risk of BMT alone is
subject to underestimation if there is loss to follow-up,
death of undetermined cause, small patient cohorts, or
crossover to repair. ACAS and ACST both grossly under-
Table I. Guidelines from various organizations for repair
Organization Year
American Academy of Neurology 2005 Stenosis 60
complic
American Heart Association 1998 Stenosis 60
stroke an
European Society of Vascular Surgery 2009 CEA recom
99% sten
be consi
Society for Vascular Surgery 2008 Stenosis 60
Table II. Perioperative risk of carotid endarterectomy in p
Source Year Pa
ACAS2 1995
ACST1 2004
US National Inpatient Sample25 2008 1
Northern New England Vascular Group26 2008
NSQIP27 2009
ACAS, Asymptomatic Carotid Atherosclerosis Study; ACST, Asymptomaticestimated the long-term benefits of repair for some of thesereasons and by curtailing follow-up soon after the benefit of
repair had been determined. Had patients been monitored
longer, the benefit of repair would likely have been greater
because the annual risk of stroke after repair was much less
than the annual risk with BMT alone.3 To put it another
way, any patient who lived more than a couple years expe-
rienced a benefit to carotid repair every year for the rest of
their lives, while every patient who did not undergo repair
continued to face an excess annual threat. In addition, it is
possible that contemporary BMT, which was not fully
implemented during ACST (70% were taking statins by
conclusion of the trial), would further decrease the small
annual risk of stroke after repair. We will learn more about
this from the Carotid Revascularization Endarterectomy vs
Stent Trial (CREST).35
Repair plus BMT was shown to be the better treatment
in ACST, even though the study was biased against CEA.
Only 91% of patients randomized to repair received it, and
18% of those randomized to BMT underwent repair. Tech-
nique and perioperative management were not standard-
ized. Had all CEA patients been taking statins and anti-
platelet agents and received a patch at surgery, risk would
likely have been lower.28,29,32 Contemporary results of
CEA show improvement and are in the range of 1.5%
stroke/death risk (Table II). The perioperative risk of
stroke and death for CEA in asymptomatic patients in
CREST was low and will serve as a benchmark.35
CAS is a maturing procedure, has improved signifi-
cantly over the past several years, and will likely continue to
improve as we better understand appropriate patient selec-
tion. Data available for CAS in asymptomatic patients out-
side of CREST comes from high-risk registries. For exam-
ple, among 516 asymptomatic patients with high-risk
anatomy for CEA, the perioperative stroke/death rate for
ymptomatic carotid stenosis
Guideline
99%. CEA can reduce future stroke rate if the perioperative
rate is kept low.16
99%. CEA indicated when it can be performed with less than 3%
ath rate.17
ded in asymptomatic men with 75 years of age with 70% to
if the perioperative stroke and death rate is 3%. CEA should
in younger, fit women.18
99%, CEA plus BMT, if the perioperative risk is low.19
ts with asymptomatic carotid stenosis
(N) Stroke (%) Death (%) Stroke/death (%)
24 . . . . . . 2.3
48 . . . . . . 2.8
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32 . . . . . . 1.4
09 0.96 0.56 1.7
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randomized to BMT plus CEA or CAS. In the lead-in
phase, the stroke/death rate for CAS was 1.3%, with no
ipsilateral strokes between 30 days and 1 year.37 Alternative
methods of cerebral protection, such as reversed flow, may
also play a role.38-40
Effort has been devoted to understand which patients
are most likely to benefit from repair. This will decrease the
number needed to treat to prevent a stroke. High-risk
groups are being identified, including those with silent
infarcts, certain plaque characteristics, microemboli on
transcranial Doppler (TCD) imaging, rapid plaque pro-
gression, and others.7,10,12,13,34,41
The bottom line: BMT plus repair was much better
than BMT alone, even in a level I study biased against
repair. BMT has improved, but other things have changed
as well. As long as the perioperative risk of repair remains
about the same as or less than the risk of BMT alone at 2
years, it will continue to benefit good-risk patients to
consider repair in addition to BMT.
WHAT IS THE EVIDENCE FOR BMT ALONE?
We have no level I data showing that BMT alone in any
era has been better than BMT plus repair. We don’t know if
the risk of BMT alone is low enough to obviate the benefits
of repair. Shouldn’t we know the answer to that before we
abandon the patients who could benefit from repair? The
assertion that BMT has solved the problem of asymptom-
atic carotid stenosis comes from several recent studies:
SMART, Oxford Vascular, Asymptomatic Carotid Stenosis
and Risk of Stroke (ACSRS) study, and studies by Spence
and Abbott.7-9,11,12 These studies are not adequate to
determine care.
The SMART study, an often-cited source for the su-
premacy of BMT, monitored 221 patients with question-
naires.8 Many of these patients would not be considered for
repair because a peak systolic velocity (PSV) of only 150
cm/s was required to be included. Only 96 patients had a
70% to 99% stenosis, with a PSV 210 cm/s. Stroke
occurred in 2.7% over 3.6 years, but 6% had CEA and 1%
had CAS. Deaths due to stroke were included in the general
category of death (15%), and we don’t know how many
deaths were stroke-related. The Oxford Vascular Study
reported a 0.34% ipsilateral stroke rate per year with BMT
alone.9 Ipsilateral transient ischemic attacks developed in
another 1.8%, and many participants went on to have CEA.
Other territory strokes occurred in 8.3% per year. Unspec-
ified vascular death occurred in 7.7%. The study monitored
101 patients with50% stenosis, but only 32 had 70% to
99% stenosis. Three of these 32 had a stroke during
follow-up.
In another line of investigation, Spence et al7 used
TCD to identify asymptomatic carotid stenosis patients
(PSV 170 cm/s) with and without microemboli.7 Those
with microemboli had a stroke risk of 10.3% the first year
and 18.5% the second year. One can only guess why all the
microemboli patients were not referred for CEA after
the first year. In those who did not have microemboli, thefirst-year risk of stroke was 1.4% and the second-year risk of
stroke was 1.8%. Although Spence et al advocate against
repair in this group (those remaining after the high-risk
microemboli patients are excluded), the cumulative 2-year
risk of stroke was approximately 3.2% with contemporary
BMT alone. This is only a little less than the 2-year stroke
risk in the all-comers BMT group in the ACST (about 4%)
and is more than twice as high as the perioperative risk of
CEA plus BMT in the CREST study.35 When other end
points were included (stroke or death or CEA) in those
with no microemboli, the risk was 6.5% at 2 years. Even in
the lower-risk group with no microemboli, the benefit of
repair in addition to BMT could be significant if repair is
provided at a low risk, in the range of 2%.
In another study, Abbott et al12 did not show such a
dramatic difference between those with and without micro-
emboli on TCD. The annual transient ischemic attack
(TIA)/stroke risk was 10% in the microemboli group and
7% in the group with no microemboli. These groups both
would likely benefit from repair as long as it can be done
with low risk. ACSRS monitored 462 patients who had
60% stenosis in relationship to bulb diameter by the
ECST method (these could be 30% diameter reduction by
North American Symptomatic Carotid Endarterectomy
Trial [NASCET] criteria). CT scans were performed to
identify those with silent cerebral infarcts. The ipsilateral
annual event rate was 4.6% when infarcts were present and
2.4% when no infarcts were present. The annual risk of
stroke was 3.6% with and 1% without silent infarcts.10
These mentioned studies have been used to extrapolate
a trend and suggest a stroke rate that approaches zero with
modern BMT.4 This is duly noted but is indirect evidence
of the benefits of BMT. These studies were generally com-
promised by a number of recurring problems: inclusion of
minimal lesions, unclear end points, mixed groups, short-
term follow-up, and only small groups with bona fide
carotid stenosis that would have been considered for repair.
In each of the aforementioned studies, for example, duplex
imaging was used to quantify carotid stenosis. The last time
that a major asymptomatic carotid study carefully analyzed
degree of stenosis by angiography was in the follow-up of
NASCET patients with asymptomatic contralateral carotid
stenosis.42 The stroke rate was 3.2% per year, and the
highest risk was in those with 75% to 94% stenosis (18.5%
stroke at 5 years). Incidentally, 80% of the strokes were not
preceded by TIA. Calls for the cessation of repair are being
made on the basis of these data, without much acknowl-
edgment of the challenges of BMT alone.
BMT is desirable and necessary and is discussed as if it
were fully formed and possible to broadly implement. In
fact, BMT is not simple to characterize or to produce. It is
challenging to accomplish in broad populations because it
is expensive, time-consuming, complicated, requires vigi-
lance and compliance, and has its own side effects and
complications.43 There are those who will not be able to
quit smoking and those who cannot tolerate statins or
antiplatelet agents. Not everyone will be convinced to take
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row’s obsolete practice.
What is the real-world risk of stroke with BMT alone,
especially over the long-term, given that there will be
noncompliance and intolerance that reduce the efficacy of
the medical regimen? Compliance with a complex medical
regimen will likely be higher in a study where investigators
go about proving biases with impractical labor-intensive
practices but likely lower in the real world. Whereas in the
real world, you have either had your carotid fixed or not. In
addition to the disadvantages of BMT, there is a downside
to lack of repair: continued annual risk of stroke in excess of
the annual risk after repair, psychologic effects of living with
a threatening lesion, and the potential of long-term cogni-
tive deterioration.44-48
Drawing ridiculous conclusions from skimpy evidence,
some have called for a cessation or severe limitation of
carotid repair.4,5,49 It is disingenuous to treat small groups
of asymptomatic patients with nonlesions, see that they
remain asymptomatic with BMT, and then claim victory.
The old risks of repair are being compared with pseudona-
tural history studies of modern BMT in patients with
lesions that might never have been considered for repair. All
the while, those with carotid stenosis could go on to have
preventable strokes without repair under a misguided and
nihilistic approach. Incidentally, what is the late follow-up
of medically managed patients who still harbor these le-
sions? We don’t have any.
CONCLUSION
Patients that present with stroke due to carotid steno-
sis, at some previous time, had an asymptomatic lesion and
an opportunity for repair. Repair of carotid stenosis, by
CEA and in some cases CAS, in addition to BMT, is
currently the best way to treat most asymptomatic patients
with 60% to 99% carotid stenosis. How well can BMT alone
handle the problem? This will take a trial and 10 years.
What we know now is that each time it was fairly evaluated,
when repair was added to BMT, it cut the risk in half. When
repair is used judiciously in concert with BMT and per-
formed well, it can have life-long protective effects against
stroke-related death and disability for patients with asymp-
tomatic carotid stenosis. We should continue to provide
repair to good-risk patients with significant asymptomatic
carotid stenosis and continue to look for ways to identify
which patients are most likely to benefit from repair.
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PART II: THE MAJORITY OF PATIENTS WITH
ASYMPTOMATIC CAROTID DISEASE DO NOT
REQUIRE INTERVENTION AND ARE BETTER
TREATED MEDICALLY.
—Professor A. Ross Naylor
Thomas Kuhn invented the term “paradigm shift.”
This occurs when
. . . scientists tend to work within one set of ideas about
how the world is. Everything they do, be it experimental
or theoretical, is informed by, and framed within, that set
of ideas. However, there will be evidence that does not fit.
At first, that evidence will be ignored or sabotaged. Even-
tually though, the anomalies will pile up so high that they
simply cannot be ignored or sabotaged any longer. Then
comes crisis.1
In this debate, I will contend that “anomalous” evidence
challenges the “one-size-fits-all” approach to treating
asymptomatic carotid disease. We need a paradigm shift in
thinking.
In the 1970s, surgeons were convinced that carotid
endarterectomy (CEA) prevented stroke in asymptomatic
patients. Their intuition was vindicated with the Asymp-
tomatic Carotid Atherosclerosis Study (ACAS)2 and the
Asymptomatic Carotid Surgery Trial (ACST),3 leading the
American Heart Association (AHA) to conclude that CEA
was “recommended in highly selected patients with high-
grade asymptomatic stenoses, provided it was performed by
surgeons with 3% morbidity and mortality.”4 This is
generally translated to mean,“CEA is appropriate in asymp-
tomatic patients with 60% to 99% stenoses.”
The AHA recommendation (updated in 2006)4 is
based on the highest level of evidence, so why the debate?
Unlike the symptomatic trials, which provided level I evi-
dence for intervention and enduring multidisciplinary con-
sensus, there is less agreement about managing asymptom-
atic patients. Notwithstanding the conservatism of some
neurologists, the only issue for many surgeons and inter-
ventionists is whether CEA or carotid artery stenting (CAS)
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significantly reduces the risk of stroke by 50%, and that
(alone) is compelling enough evidence for intervening.
Using Kuhn’s principle, they are “working within one set of
ideas about how the world is.” They are also hostile to
anyone who suggests that their reasoning might be flawed.
The AHA recommendation includes the phrase “highly-
selected.” Unfortunately, no clarification was forthcoming
about what this meant, and physicians have to interpret this
for themselves; in reality, it is ignored. However, defining
who benefits most—and least—from intervention is crucial
to this debate and brings us to those anomalies that chal-
lenge current guidelines and support a paradigm shift in
thinking. These are chronologically listed in the Table, and
the most important will be debated after reviewing how
critics responded to them.
Physicians have (not unreasonably) adopted the role of
patient advocate should anyone suggest that intervention
might be unnecessary:
1. “You would never send someone home with occlusive
disease of the left main coronary artery. Why then would
you send home a patient with a critical stenosis of a
dominant-hemisphere internal carotid with a 95% ste-
nosis?”34
2. “It is politically untenable to deny women, and not men
prophylactic CEA.”35
3. “But what about the patient? He understands that his
brain is threatened by a severe carotid stenosis, no
matter what the overall percentage of this threat actually
is. They should also understand that denying surgery
equates to being exposed life-long to a cumulative risk
of a cerebrovascular event.”36
Vox populi comments include:
1. “As long as 80% of strokes are not preceded by a TIA, I
will treat asymptomatic patients.”
2. “Women live longer, therefore it is unreasonable to
withhold CEA/CAS.”
3. “Patients are not always compliant with taking medica-
tions. It is safer to offer CEA.”
4. “Surgeons need to focus on the welfare of the individual
and not the population.”
Next comes media hype, a classic example being the
1994 New York Times commentary (after the ACAS Alert)
which stated that “50% fewer strokes will occur if asymp-
tomatic individuals with 60% stenoses are submitted to
surgery.”37 This, I suspect, is a commonly quoted statistic
when risk/benefit is discussed with patients. It is also a
good example of being “economical with the actualité.”
Methodologic criticisms include:
1. “As experts in this domain, we should rely on strong,
though not necessarily fully evidence based arguments
and draw our own conclusions about the case of our
specific patient.”36
2. “Subgroup analyses can be ignored as the trials were
never powered to make these conclusions.”3. “These data are from very old studies and have little
relevance in today’s world, especially now that CAS is
available.”
Realities of professional life (conceded “off the
record”) include “if I do not operate on this patient,
someone else will and I will lose income.” Finally, if all else
fails, why not resort to censure: (1) “why should we, who
work in a first-world health service, pay any attention to
someone working in a third-world system” (2005 Charing
Cross Symposium), and (2) “what is more paradoxical is
the attitude of some who become progressive opinion
leaders, despite the fact that the message they deliver is a
deliberate and insistent non-operating pleading in the case
of asymptomatic disease. Using mostly statistical or eco-
nomic arguments, rather than medical evidence, they aim
to demonstrate that prophylactic CEA, even in being prob-
ably the safest approach in skilled hands, was not medically
justified, nor cost-effective for public savings.”36 Ouch!
The preceding counterarguments to the anomalies in
the Table mask a growing crisis, primarily because some are
now too important to remain ignored:
First, ACAS/ACST showed that almost 90% of medi-
cally treated patients were never destined to suffer a stroke
5 years.2,3 That should, of course, make me the winner in
this debate (read the title), but I see you remain uncon-
vinced.
Second, is the uncomfortable observation that even if
you could treat everyone fulfilling ACAS criteria with a
2.3% procedural risk, 95% of strokes will still happen.6,29
This is because CEA/CAS cannot prevent the 70% of
strokes unrelated to carotid disease, while two-thirds of
patients with carotid origin strokes will not have significant
stenoses and 15% to 20% will present with a TIA. That
leaves about 8 to 10 patients whose strokes will be attrib-
utable to significant, asymptomatic carotid disease in whom
to target interventions. However, CEA reduces stroke by
50%, so that only five strokes (at most) will be prevented.
Consider that the next time someone justifies mass inter-
vention because “80% of strokes are unheralded.”
If you still believe that CEA/CAS confers benefit in
most asymptomatic patients, have you considered the lo-
gistics of finding and treating them? With a population of
1.3 million in Hawaii, let us assume that Peter Schneider
and his colleagues can somehow identify the 1% of Hawai-
ians (13,000) with an asymptomatic 60% to 99% stenosis
(this would normally take years). Assuming theater/cathe-
ter suites work every weekday (260 per annum) and 10
CEA/CAS procedures are performed somewhere on the
island on every one of these days (ie, 2600 interventions in
asymptomatic patients per year; quite a big task), it would
take 5 years to clear the backlog. During this time, some
will suffer a stroke whilst awaiting treatment and more
“at-risk” populations will emerge. In reality, a policy of
operating on as many asymptomatic patients as possible will
only prevent about 1% of all strokes.
But mass interventions consume resources. Using
ACAS data, performing CEA/CAS with a 2.3% risk pre-
Caro
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(indisputable fact). The number of “any” strokes preven-
ted 51. In 2005, 122,986 revascularizations were under-
taken in asymptomatic patients in the United States of
America (USA),19 and simple calculation (59  122.986)
shows that ipsilateral strokes will be prevented in only 7256
patients. This also means that in 2005, 115,730 (94%)
underwent an ultimately unnecessary intervention. Using
USA financial data,19 unnecessary interventions cost USA
health providers $2.1 billion each year.28,29 That is surely
unsustainable.
Ah, but you probably feel that my debate has focussed
excessively on logistics, cold statistics, and expenditure, and
not enough on the individual patient? No, I would not
allow that. Notwithstanding the 30-plus anomalies detailed
in the Table, the single most important reason why a
paradigm shift in thinking is unavoidable is because the
most venerated of “sacred cows” is now under threat. That
Table. Anomalies regarding a “one-size-fits-all” policy of
stenting (CAS) to “standard-risk” patients with 60% to 99
1991 ACAS: 40% of surgeon applicants rejected, raising q
1995 ACAS: With a 2.3% procedural risk, CEA prevents o
ACAS: With procedural risk included, CEA conferre
ACAS: No relationship between stenosis severity/b
Even if you could treat every patient, 95% of all stro
1996 Hertzer concedes that the annual risk of stroke in A
ACAS: Even with the procedural risk excluded, CEA
First editorial to question whether ACAS results wa
1997 Canadian Neurologists & Stroke Physicians recomm
2000 ACAS: CEA does not confer significant benefit in p
Fifty-five percent of late strokes are cardioembolic o
embolism)12
2001 Seven of 10 states in USA report procedural risks 
Using ACST entry criteria, the average procedural r
2002 ACAS: Had their data been analyzed at 4 years, CE
2003 European Stroke Initiative suggests that medical tre
Editorial suggests that the randomized trials should
2004 ACST: CEA conferred no benefit in patients aged 
ACST: No association between stenosis severity/bil
ACST: If procedural risk included, CEA conferred n
ACST: Most of the benefit was seen in patients with
Using ACST inclusion criteria, the average procedu
Meta-analysis of 46 contemporary surgical studies fo
compared with outcomes in ACAS18
2005 Ninety-two percent of all carotid revascularizations
2007 US Task Force recommends against screening (bene
Annual risk of stroke in medically treated patients h
2008 Published evidence that high statin therapy stabilize
Even with 15-year follow-up, it is never cost-effectiv
New England Journal of Medicine poll: 50% of respo
Editorial suggests that it may be time to stop interv
If the procedural risk of death/disabling stroke was
CEA/CAS will not confer any long-term benefit2
2009 Systematic review: Noninterventional therapy now s
and is 3 to 8 times more cost-effective27
94% of CEA/CAS procedures in the US are ultimat
Evidence of sustained decline in annual stroke risk i
2010 Evidence that high statin therapy significantly reduc
Meta-analysis of 3 recent studies (1635 patients); ip
More calls for randomized trials comparing CEA wi
ACAS, Asymptomatic Carotid Atherosclerosis Study; ACST, Asymptomaticis the basic assumption that the annual rate of stroke inmedically treated patients remains about 2%. If the annual
risk has decreased since ACAS/ACST results were pub-
lished, many of the risk/benefit calculations become vul-
nerable to challenge. If the annual risk falls to 1%, it is
unlikely that CEA/CAS could ever confer significant ben-
efit.27 What would you think if I suggested that the annual
risk of ipsilateral stroke may now be as low as 0.5% to 0.7%?
Abbott was one of the first to observe that the annual
risk of stroke in medically treated patients has declined
significantly during last 20 years,21,25,27 and her latest
meta-analysis concludes that noninterventional therapy is
the safer option, while also being more cost-effective.26 A
second (smaller) meta-analysis published in 2010 included
natural history data from three studies recruiting after 2000
and found that the average annual risk of ipsilateral stroke
in 1635 medically treated patients was 0.5%.30 Abbott (and
others) have attributed this decline in stroke risk to im-
provements in BMT, especially through the use of high-
ing carotid endarterectomy (CEA) or carotid artery
mptomatic carotid stenoses
ns about generalizability5
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benefit in women2
l disease and late stroke risk2
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primarily because some studies in Abbott’s meta-analysis
included patients with stenoses of 50% to 99% as opposed
to 60% to 99%. However, neither ACAS/ACST nor a raft
of natural history studies have consistently shown that late
stroke is associated with stenosis severity.2,3,28 Moreover,
an alternative interpretation of data from ACAS and ACST
suggests that they, too, have encountered year-on-year
reductions in stroke risk. They just haven’t acknowledged it
yet. ACAS published 5-year data in 1995, ACST in 2004,
and then released 6- to 10-year data during 2008 and
2009,2,3,28 giving observers three sequential 5-year periods
for comparison. In 1995, ACAS reported a 5-year risk of
any stroke of 17.5% (ie, 3.5% per annum) in medically
treated patients. The risk of any stroke in years 1 to 5 of
ACST fell to 11.8% (ie, 2.4% per annum), whereas in years
6 to 10, the second 5-year period of study, the risk of any
stroke decreased to 7.2% (ie, 1.4% per annum). In 1995,
ACAS reported a 5-year risk of ipsilateral stroke of 11.0%
(ie, 2.2% per annum) in medically treated patients. By
2004, the 5-year risk of ipsilateral stroke in ACST had fallen
to 5.3% (ie, 1.1% per annum), whereas in the second
five-year period (years 6-10 of ACST), the risk of ipsilateral
stroke decreased to 3.6% (ie, 0.7% per annum). This means
that the average annual risk of any stroke has declined by
60%, from 3.5% to 1.4%, in the 15 years since ACAS
published, whereas the annual average risk of ipsilateral
stroke has declined by 67% from 2.2% to 0.7%. This, in
conjunction with Abbott’s meta-analysis, suggests that
there has been a significant, sustained decrease in the an-
nual risk of stroke.
So who will win this debate? The paradox is that I can
neither win nor lose. Until influential bodies (ie, the AHA)
consider the implications of a declining stroke risk and
revise their recommendation (ie, triggering a paradigm
shift in thinking), nothing will change. This is because the
AHA wields the greatest influence over practice worldwide
and surgeons and interventionists will continue to offer
mass interventions, not least to minimize medicolegal cen-
sure. To many observers,28,32,33 including the principle
investigator of CREST,32 we need to undertake an ade-
quately powered randomized trial that includes treatment
arms for CEA, CAS, and BMT. This should make it possi-
ble to test algorithms for identifying “high-risk for stroke”
subgroups, for example, TCD embolization, silent infarc-
tion on CT, incomplete circle of Willis, computerized
plaque morphology, and biomarkers. Surely we must focus
resources toward intervening in only a very small cohort of
“high-risk for stroke” patients?
Conversely, it is also true that I cannot lose this debate.
It is indisputable that the vast majority of patients with
asymptomatic carotid disease will never suffer a stroke; only
1% of strokes will be prevented through a mass campaign of
uncritical intervention, 94% of interventions in asymptom-
atic patients are ultimately unnecessary, and the annual risk
of stroke is now very much lower than it was in 1995. How
else could you interpret the data? Unless, of course, you
remain distracted by other conflicts of interest . . . .REFERENCES
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8, 2009.Submitted May 12, 2010; accepted May 13, 2010.COMMENTARYThomas L. Forbes, MD, London, Ontario, Canada
Dr Schneider and Prof Naylor have offered a spirited debate
regarding the optimal approach to patients with significant asymp-
tomatic carotid artery stenoses. Their arguments are clear, reasoned,
passionate, and in direct opposition with each other. Both would
agree that stroke in patients with asymptomatic stenoses is a relatively
rare event, and, given its potentially devastating consequences, should
be avoided. Further points of agreement are few and far between.
Most issues of contention are a result of differing interpretations of
the same data or studies. For example, Prof Naylor’s claim that stroke risk
is declining with medical therapy is supported by several studies with
which Dr Schneider has issue given their inclusion of patients with lesser
degrees of stenosis who would not have been surgical candidates in the
firstplace.ProfNaylorcounterswith theargument that strokeriskhasnot
been consistently shown to be directly related to degree of stenosisIn any event, strategies consisting of medical therapy alone
or combined with surgical intervention have both proven highly
successful at preventing stroke in asymptomatic patients. Innu-
merable studies offer support, and few would argue with this.
Where controversy remains, and will probably always persist,
is in which instances should one strategy be chosen over an-
other? Our debaters both recommend another study to help to
answer these questions, but I suspect that such a study’s data
would continue to be interpreted differently depending on what
side of the argument one sits. This likely will remain a polarizing
issue.
So, although convincing, Dr Schneider and Prof Naylor have
probably not succeeded in persuading each other to change their
approaches, but have certainly gone a long way in educating the
rest of us.
